Literature DB >> 12806885

Applications of recombinant Leishmania amazonensis expressing egfp or the beta-galactosidase gene for drug screening and histopathological analysis.

Takahiro Okuno1, Yasuyuki Goto, Yoshitsugu Matsumoto, Haruki Otsuka, Yasunobu Matsumoto.   

Abstract

Leishmania amazonensis recombinants expressing the enhanced green fluorescent protein (egfp) gene or beta-galactosidase gene (lacZ) were constructed for drug screening and histopathological analysis. The egfp or lacZ in a leishmanial transfection vector, p6.5, was introduced into L. amazonensis promastigotes, and egfp or lacZ-carrying recombinant L. amazonensis, La/egfp and La/lacZ, respectively, were obtained. Expression of egfp or lacZ in both promastigotes and amastigotes could be clearly visualized by fluorescence microscopy or by light microscopy with 5-bromo-4-chloro-3-indolyl-beta-D-galactopyranoside (X-Gal), respectively. Fluorescence signal and beta-galactosidase activity measured by a colorimetric reaction with chlorophenol red beta-D-galactopyranoside (CPRG) were well correlated to the numbers of these parasites. The inhibitory concentration (IC50) of a leishmanicidal drug, amphotericin B, in L. amazonensis promastigotes measured using La/egfp and La/lacZ was similar to that measured by conventional methods such as cell counting, thymidine incorporation and colorimetric assay. Furthermore, the fluorescence signal and absorbance of CPRG correlated well with the numbers of La/egfp and La/lacZ amastigotes in macrophages, respectively, suggesting La/egfp and La/lacZ can be a convenient and useful tool for drug screening not only in promastigotes, but also in amastigotes of L. amazonensis. La/lacZ collected from mouse tissues four weeks after the parasite infection were stained well with X-Gal. La/lacZ allowed parasite detection at high sensitivity in the tissues of infected mice and will be useful for following infections in macrophages in vivo. Thus, the marker-transfected Leishmania parasites constructed in this study will be useful for analyses of Leishmania parasites, especially at the intracellular stage.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12806885     DOI: 10.1538/expanim.52.109

Source DB:  PubMed          Journal:  Exp Anim        ISSN: 0007-5124


  16 in total

1.  An alternative in vitro drug screening test using Leishmania amazonensis transfected with red fluorescent protein.

Authors:  Marcele N Rocha; Célia M Corrêa; Maria N Melo; Stephen M Beverley; Olindo Assis Martins-Filho; Ana Paula Madureira; Rodrigo P Soares
Journal:  Diagn Microbiol Infect Dis       Date:  2013-01-10       Impact factor: 2.803

2.  Real-time in vivo green fluorescent protein imaging of a murine leishmaniasis model as a new tool for Leishmania vaccine and drug discovery.

Authors:  Sanjay R Mehta; Robert Huang; Meng Yang; Xing-Quan Zhang; Bala Kolli; Kwang-Poo Chang; Robert M Hoffman; Yasuyuki Goto; Roberto Badaro; Robert T Schooley
Journal:  Clin Vaccine Immunol       Date:  2008-10-22

3.  Simple colorimetric trypanothione reductase-based assay for high-throughput screening of drugs against Leishmania intracellular amastigotes.

Authors:  Erika van den Bogaart; Gerard J Schoone; Paul England; Dorien Faber; Kristina M Orrling; Jean-Claude Dujardin; Shyam Sundar; Henk D F H Schallig; Emily R Adams
Journal:  Antimicrob Agents Chemother       Date:  2013-11-04       Impact factor: 5.191

4.  Leishmania (Viannia) panamensis: an in vitro assay using the expression of GFP for screening of antileishmanial drug.

Authors:  Rubén E Varela M; Diana Lorena Muñoz; Sara M Robledo; Bala K Kolli; Sujoy Dutta; Kwang Poo Chang; Carlos Muskus
Journal:  Exp Parasitol       Date:  2009-03-20       Impact factor: 2.011

Review 5.  Visceral leishmaniasis: experimental models for drug discovery.

Authors:  Suman Gupta
Journal:  Indian J Med Res       Date:  2011-01       Impact factor: 2.375

6.  Use of in vivo and in vitro systems to select Leishmania amazonensis expressing green fluorescent protein.

Authors:  Solange dos Santos Costa; Marjorie de Assis Golim; Bartira Rossi-Bergmann; Fabio Trindade Maranhão Costa; Selma Giorgio
Journal:  Korean J Parasitol       Date:  2011-12-16       Impact factor: 1.341

7.  Leishmania amastigotes as targets for drug screening.

Authors:  Adriano Monte-Alegre; Ali Ouaissi; Denis Sereno
Journal:  Kinetoplastid Biol Dis       Date:  2006-10-23

8.  Development of a Fluorescent Assay to Search New Drugs Using Stable tdTomato-Leishmania, and the Selection of Galangin as a Candidate With Anti-Leishmanial Activity.

Authors:  María Fernanda García-Bustos; Agustín Moya Álvarez; Cecilia Pérez Brandan; Cecilia Parodi; Andrea Mabel Sosa; Valeria Carolina Buttazzoni Zuñiga; Oscar Marcelo Pastrana; Paula Manghera; Pablo Alejandro Peñalva; Jorge Diego Marco; Paola Andrea Barroso
Journal:  Front Cell Infect Microbiol       Date:  2021-06-04       Impact factor: 5.293

9.  Stage-regulated GFP Expression in Trypanosoma cruzi: applications from host-parasite interactions to drug screening.

Authors:  Rafael Luis Kessler; Daniela Fiori Gradia; Rita de Cássia Pontello Rampazzo; Édio Elígio Lourenço; Nilson José Fidêncio; Lauro Manhaes; Christian Macagnan Probst; Andréa Rodrigues Ávila; Stenio Perdigão Fragoso
Journal:  PLoS One       Date:  2013-06-20       Impact factor: 3.240

10.  Appraisal of a Leishmania major strain stably expressing mCherry fluorescent protein for both in vitro and in vivo studies of potential drugs and vaccine against cutaneous leishmaniasis.

Authors:  Estefania Calvo-Álvarez; Nestor Adrian Guerrero; Raquel Alvarez-Velilla; Christopher Fernández Prada; Jose María Requena; Carmen Punzón; Miguel Ángel Llamas; Francisco J Arévalo; Luis Rivas; Manuel Fresno; Yolanda Pérez-Pertejo; Rafael Balaña-Fouce; Rosa M Reguera
Journal:  PLoS Negl Trop Dis       Date:  2012-11-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.